The Journal of Allergy and Clinical Immunology, October 2017, Vol.140(4), pp.982-984
To link to full-text access for this article, visit this link: http://dx.doi.org/10.1016/j.jaci.2017.04.034 Byline: Erika Jensen-Jarolim (a)(b), Michelle C. Turner (c)(d)(e)(f), Sophia N. Karagiannis (g)(h) Author Affiliation: (a) Institute of Pathophysiology and Allergy Research, Center of Pathophysiology, Infectiology and Immunology, Medical University Vienna, Vienna, Austria (b) The Interuniversity Messerli Research Institute, University of Veterinary Medicine Vienna, Medical University Vienna and University Vienna, Vienna, Austria (c) Barcelona Institute for Global Health (ISGlobal), Barcelona, Spain (d) Universitat Pompeu Fabra (UPF), Barcelona, Spain (e) CIBER Epidemiolog?a y Salud P?blica (CIBERESP), Madrid, Spain (f) McLaughlin Centre for Population Health Risk Assessment, University of Ottawa, Ottawa, Ontario, Canada (g) St John's Institute of Dermatology, Division of Genetics & Molecular Medicine, Faculty of Life Sciences and Medicine, King's College London, London, United Kingdom (h) NIHR Biomedical Research Centre at Guy's and St Thomas' Hospitals and King's College London, Guy's Hospital, King's College London, London, United Kingdom Article History: Received 31 January 2017; Revised 8 March 2017; Accepted 5 April 2017 Article Note: (footnote) Supported by the European Academy for Allergy and Clinical Immunology, as an initiative of its AllergoOncology Task Force. E.J.-J. was supported by the Austrian Science Fund FWF (grant SFB F4606-B28). S.N.K. was supported by the National Institute for Health Research (NIHR) Biomedical Research Centre (BRC) based at Guy's and St Thomas' NHS Foundation Trust and King's College London. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health. S.N.K. was also supported by the Medical Research Council (MR/L023091/1), Cancer Research UK (C30122/A11527; C30122/A15774), the Academy of Medical Sciences, Breakthrough Breast Cancer (147), and the CR UK/NIHR in England/DoH for Scotland, Wales, and Northern Ireland Experimental Cancer Medicine Centre (C10355/A15587). ISGlobal is a member of the CERCA Programme, Generalitat de Catalunya., Disclosure of potential conflict of interest: E. Jensen-Jarolim has received grants from the Austrian Science Fund (SFB F4606-B28), has received travel support from the European Academy of Allergy and Clinical Immunology, has consultant arrangements with Allergy Therapeutics, and has received payment for lectures from Allergy Therapeutics and Thermo Fisher. M. C. Turner has consultant arrangements with ICF Incorporated. S. N. Karagiannis has received grants from the NIHR Biomedical Research Centre at Guy's and St Thomas's Hospitals NHS Trust and King's College London, the Medical Research Council, Cancer Research UK, the Academy of Medical Sciences, Breast Cancer Now, and CR UK/NIHR in England/DOH for Scotland, Wales, and Northern Ireland Experimental Cancer Medicine Centre and has received travel support from the European Academy of Allergy and Clinical Immunology.
Allergy ; Cancer ; Tumor ; Tolerance ; Ige ; Effector Cells ; Antibody-Dependent Cell-Mediated Cytotoxicity ; Allergooncology ; Clinical Oncology ; Oncoimmunology ; Medicine
View record in ScienceDirect (Access to full text may be restricted)
View full text in ScienceDirect